Dawn Sauro serves as the Chief Growth Officer (CGO) at WCG Clinical where she is responsible for the company’s enterprise growth and commercialization strategy to drive sustainable and profitable growth and revenue. Representing the voice of the customer throughout WCG, Dawn works with WCG’s world-class sales and marketing teams in an aligned go-to-market model that leads with exceptional science, innovation, and delivery. Having more than 30 years of drug and device development experience, Dawn is an experienced drug development and clinical research expert, strategist, and leader who leverages her extensive industry experience and client relationships to consistently deliver on aggressive top- and bottom-line growth.
Prior to joining WCG, Dawn served as Elligo’s Chief Operating Officer (COO) where she helped to further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions. Dawn was also the Chief Development Officer at Clinipace Clinical Research (now Caidya) where she developed the strategy and grew the organization to be a trusted partner for sponsors, delivering clinical trials across a variety of therapeutic areas. Prior roles also included President, Development Innovations at Sarah Cannon where she led the full-service Oncology CRO and Senior Vice President and General Manager, Hematology/Oncology at inVentiv Health (now Syneos).
Dawn holds a Bachelor of Science degree from the University of Rhode Island.